Emergent BioSolutions (EBS) Initiates Phase 1b Study of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia  
10/31/2012 7:42:57 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today the initiation of a Phase 1b study (Protocol 16009) of TRU-016 in combination with rituximab for patients with previously untreated chronic lymphocytic leukemia (CLL). TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies.